These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 24180479)

  • 41. Management of metastatic prostate cancer: the crucial role of geriatric assessment.
    Droz JP; Chaladaj A
    BJU Int; 2008 Mar; 101 Suppl 2():23-9. PubMed ID: 18307689
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone.
    ; Berry DL; Moinpour CM; Jiang CS; Ankerst DP; Petrylak DP; Vinson LV; Lara PN; Jones S; Taplin ME; Burch PA; Hussain MH; Crawford ED
    J Clin Oncol; 2006 Jun; 24(18):2828-35. PubMed ID: 16782921
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Intravenous vinorelbine as first line chemotherapy in patients with castration-resistant prostate cancer].
    Grenader T; Plotkin Y; Rosengarten O
    Harefuah; 2014 Dec; 153(12):731-4, 752. PubMed ID: 25654915
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Randomised phase II/III study of docetaxel with or without risedronate in patients with metastatic Castration Resistant Prostate Cancer (CRPC), the Netherlands Prostate Study (NePro).
    Meulenbeld HJ; van Werkhoven ED; Coenen JL; Creemers GJ; Loosveld OJ; de Jong PC; Ten Tije AJ; Fosså SD; Polee M; Gerritsen W; Dalesio O; de Wit R
    Eur J Cancer; 2012 Nov; 48(16):2993-3000. PubMed ID: 22677260
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
    Meyer A; Cygan P; Tolzien K; Galvez AG; Bitran JD; Lestingi TM; Nabhan C
    Clin Genitourin Cancer; 2014 Apr; 12(2):100-5. PubMed ID: 24169494
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Practical guide to the use of chemotherapy in castration resistant prostate cancer.
    Petrylak DP
    Can J Urol; 2014 Apr; 21(2 Supp 1):77-83. PubMed ID: 24775728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Estimation of tumour regression and growth rates during treatment in patients with advanced prostate cancer: a retrospective analysis.
    Wilkerson J; Abdallah K; Hugh-Jones C; Curt G; Rothenberg M; Simantov R; Murphy M; Morrell J; Beetsch J; Sargent DJ; Scher HI; Lebowitz P; Simon R; Stein WD; Bates SE; Fojo T
    Lancet Oncol; 2017 Jan; 18(1):143-154. PubMed ID: 27979599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Oncological outcome of docetaxel-based chemotherapy for Japanese men with metastatic castration-resistant prostate cancer.
    Miyake H; Sakai I; Terakawa T; Harada K; Fujisawa M
    Urol Oncol; 2013 Aug; 31(6):733-8. PubMed ID: 21782481
    [TBL] [Abstract][Full Text] [Related]  

  • 50. High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
    Gyan E; Damotte D; Courby S; Sénécal D; Quittet P; Schmidt-Tanguy A; Banos A; Le Gouill S; Lamy T; Fontan J; Maisonneuve H; Alexis M; Dreyfus F; Tournilhac O; Laribi K; Solal-Céligny P; Arakelyan N; Cartron G; Gressin R;
    Br J Haematol; 2013 Jul; 162(2):240-9. PubMed ID: 23692641
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Carboplatin plus etoposide in heavily pretreated castration-resistant prostate cancer patients.
    Buonerba C; Federico P; Bosso D; Puglia L; Policastro T; Izzo M; Perri F; Vittoria Scarpati GD; Ferro M; Cobelli OD; De Placido S; Aieta M; Imbimbo C; Longo N; Di Lorenzo G
    Future Oncol; 2014 Jun; 10(8):1353-60. PubMed ID: 25052746
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain.
    Ernst DS; Tannock IF; Winquist EW; Venner PM; Reyno L; Moore MJ; Chi K; Ding K; Elliott C; Parulekar W
    J Clin Oncol; 2003 Sep; 21(17):3335-42. PubMed ID: 12947070
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904).
    Kudoh S; Takeda K; Nakagawa K; Takada M; Katakami N; Matsui K; Shinkai T; Sawa T; Goto I; Semba H; Seto T; Ando M; Satoh T; Yoshimura N; Negoro S; Fukuoka M
    J Clin Oncol; 2006 Aug; 24(22):3657-63. PubMed ID: 16877734
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Current and emerging treatment modalities for metastatic castration-resistant prostate cancer.
    Bracarda S; Logothetis C; Sternberg CN; Oudard S
    BJU Int; 2011 Apr; 107 Suppl 2():13-20. PubMed ID: 21382150
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Randomised phase II study of second-line olaratumab with mitoxantrone/prednisone versus mitoxantrone/prednisone alone in metastatic castration-resistant prostate cancer.
    Hakenberg OW; Perez-Gracia JL; Castellano D; Demkow T; Ali T; Caffo O; Heidenreich A; Schultze-Seemann W; Sautois B; Pavlik I; Qin A; Novosiadly RD; Shahir A; Ilaria R; Nippgen J
    Eur J Cancer; 2019 Jan; 107():186-195. PubMed ID: 30573277
    [TBL] [Abstract][Full Text] [Related]  

  • 56. First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?
    Michels J; Montemurro T; Murray N; Kollmannsberger C; Nguyen Chi K
    Cancer; 2006 Mar; 106(5):1041-6. PubMed ID: 16456811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Taxanes in the management of metastatic castration-resistant prostate cancer: efficacy and management of toxicity.
    Schutz FA; Buzaid AC; Sartor O
    Crit Rev Oncol Hematol; 2014 Sep; 91(3):248-56. PubMed ID: 24613528
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Safety and effectiveness of the radium-223-taxane treatment sequence in patients with metastatic castration-resistant prostate cancer in a global observational study (REASSURE).
    Higano CS; Dizdarevic S; Logue J; Richardson T; George S; de Jong I; Tomaszewski JJ; Saad F; Miller K; Meltzer J; Sandström P; Verholen F; Tombal B; Sartor O
    Cancer; 2024 Jun; 130(11):1930-1939. PubMed ID: 38340349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.
    Moore MJ; Osoba D; Murphy K; Tannock IF; Armitage A; Findlay B; Coppin C; Neville A; Venner P; Wilson J
    J Clin Oncol; 1994 Apr; 12(4):689-94. PubMed ID: 7512127
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Chemotherapy of the hormone-refractory prostate cancer].
    Heine K; Wolff JM
    Aktuelle Urol; 2004 Jun; 35(3):209-14. PubMed ID: 15258854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.